Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Journal of Nephrology
Erschienen in: Journal of Nephrology 3/2020

01.06.2020 | Review

Phosphate binders in chronic kidney disease: an updated narrative review of recent data

verfasst von: Jürgen Floege

Erschienen in: Journal of Nephrology | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Abstract

Chronic kidney disease (CKD) is frequently accompanied by hyperphosphatemia. High serum phosphate usually requires dietary measures, adequate dialysis prescription and/or phosphate binders. For this narrative review a PubMed searched was undertaken to identify new publications on phosphate binders that had been published between January 2015 and July 2019. The present review summarizes this most recent information on dietary measures and their problems in treating hyperphosphatemia in CKD patients, overall effects of phosphate binders on cardiovascular mortality and morbidity, adherence to phosphate binder therapy as well as new data on specific aspects of the various phosphate binders on the market: calcium-containing phosphate binders, polymeric phosphate binders (sevelamer, bixalomer, colestilan), magnesium-containing phosphate binders, lanthanum carbonate, ferric citrate, sucroferric oxyhydroxide, and new compounds in development, in particular drugs targeting intestinal phosphate transporters.
Literatur
1.
Akizawa T, Origasa H, Kameoka C, Tsukada J, Kuroishi K, Yamaguchi Y (2016) Bixalomer in hyperphosphatemic patients with chronic kidney disease not on dialysis: phase 3 randomized trial. Ther Apher Dial 20:588–597PubMed
2.
Akizawa T, Tsukada J, Kameoka C, Kuroishi K, Yamaguchi Y (2017) Long-term safety and efficacy of bixalomer in hyperphosphatemic patients with chronic kidney disease not on dialysis. Ther Apher Dial 21:173–179PubMed
3.
Awad C, Gilkison K, Shaw E (2019) Lanthanum phosphate binder-induced iron deficiency anaemia. BMJ Case Rep 12:e226157PubMed
4.
Ban S, Suzuki S, Kubota K, Ohshima S, Satoh H, Imada H, Ueda Y (2017) Gastric mucosal status susceptible to lanthanum deposition in patients treated with dialysis and lanthanum carbonate. Ann Diagn Pathol 26:6–9PubMed
5.
Bhandari SK, Liu IA, Kujubu DA, Huynh T, Behayaa H, Kovesdy CP, Kalantar-Zadeh K, Jacobsen SJ, Sim JJ (2017) Use of phosphorus binders among non-dialysis chronic kidney disease patients and mortality outcomes. Am J Nephrol 45:431–441PubMed
6.
Block GA, Block MS, Smits G, Mehta R, Isakova T, Wolf M, Chertow GM (2019) A pilot randomized trial of ferric citrate coordination complex for the treatment of advanced CKD. J Am Soc Nephrol 30:1495–1504PubMed
7.
Block GA, Pergola PE, Fishbane S, Martins JG, LeWinter RD, Uhlig K, Neylan JF, Chertow GM (2019) Effect of ferric citrate on serum phosphate and fibroblast growth factor 23 among patients with nondialysis-dependent chronic kidney disease: path analyses. Nephrol Dial Transplant 34:1115–1124PubMed
8.
Cataldo E, Columbano V, Nielsen L, Gendrot L, Covella B, Piccoli GB (2018) Phosphate binders as a cause of hypothyroidism in dialysis patients: practical indications from a review of the literature. BMC Nephrol 19:155PubMedPubMedCentral
9.
Chertow GM, Block GA, Neylan JF, Pergola PE, Uhlig K, Fishbane S (2017) Safety and efficacy of ferric citrate in patients with nondialysis-dependent chronic kidney disease. PLoS One 12:e0188712PubMedPubMedCentral
10.
Covic AC, Floege J, Ketteler M, Sprague SM, Lisk L, Rakov V, Rastogi A (2017) Iron-related parameters in dialysis patients treated with sucroferric oxyhydroxide. Nephrol Dial Transplant 32:1330–1338PubMed
11.
Coyne DW, Ficociello LH, Parameswaran V, Anderson L, Vemula S, Ofsthun NJ, Mullon C, Maddux FW, Kossmann RJ, Sprague SM (2017) Real-world effectiveness of sucroferric oxyhydroxide in patients on chronic hemodialysis: a retrospective analysis of pharmacy data. Clin Nephrol 88:59–67PubMedPubMedCentral
12.
Diaz-Tocados JM, Peralta-Ramirez A, Rodriguez-Ortiz ME, Raya AI, Lopez I, Pineda C, Herencia C, Montes de Oca A, Vergara N, Steppan S, Pendon-Ruiz de Mier MV, Buendia P, Carmona A, Carracedo J, Alcala-Diaz JF, Frazao J, Martinez-Moreno JM, Canalejo A, Felsenfeld A, Rodriguez M, Aguilera-Tejero E, Almaden Y, Munoz-Castaneda JR (2017) Dietary magnesium supplementation prevents and reverses vascular and soft tissue calcifications in uremic rats. Kidney Int 92:1084–1099PubMed
13.
Duff EA, Chawke FM (2017) A service review to assess if innovative intensive phosphate dietary education can help reduce phosphate levels to the recommended range in a hemodialysis population. Hemodial Int 21(Suppl 2):S22–S26PubMed
14.
El Borolossy R, El Wakeel LM, El Hakim I, Sabri N (2016) Efficacy and safety of nicotinamide in the management of hyperphosphatemia in pediatric patients on regular hemodialysis. Pediatr Nephrol 31:289–296PubMed
15.
Evsanaa B, Liu I, Aliazardeh B, Mahdavi S, Bajwa G, Gula J, Tam M, Sze E, Roscoe JM, Tam PY, Sikaneta T (2015) MgCaCO3 versus CaCO3 in peritoneal dialysis patients–a cross-over pilot trial. Perit Dial Int 35:31–34PubMedPubMedCentral
16.
Fissell RB, Karaboyas A, Bieber BA, Sen A, Li Y, Lopes AA, Akiba T, Bommer J, Ethier J, Jadoul M, Pisoni RL, Robinson BM, Tentori F (2016) Phosphate binder pill burden, patient-reported non-adherence, and mineral bone disorder markers: findings from the DOPPS. Hemodial Int 20:38–49PubMed
17.
Floege J (2016) Phosphate binders in chronic kidney disease: a systematic review of recent data. J Nephrol 29:329–340PubMed
18.
Floege J, Covic AC, Ketteler M, Mann J, Rastogi A, Spinowitz B, Rakov V, Lisk LJ, Sprague SM (2017) One-year efficacy and safety of the iron-based phosphate binder sucroferric oxyhydroxide in patients on peritoneal dialysis. Nephrol Dial Transplant 32:1918–1926PubMed
19.
Floege J, Covic AC, Ketteler M, Rastogi A, Chong EM, Gaillard S, Lisk LJ, Sprague SM, Group PAS (2014) A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients. Kidney Int 86:638–647PubMedPubMedCentral
20.
Fujii H, Kono K, Nakai K, Goto S, Nishii T, Kono A, Nishi S (2018) Effects of lanthanum carbonate on coronary artery calcification and cardiac abnormalities after initiating hemodialysis. Calcif Tissue Int 102:310–320PubMed
21.
Gao Y, Wang G, Li Y, Lv C, Wang Z (2019) Effects of oral activated charcoal on hyperphosphatemia and vascular calcification in Chinese patients with stage 3–4 chronic kidney disease. J Nephrol 32:265–272PubMed
22.
Goto K, Goto S, Fujii H, Watanabe K, Kono K, Nishi S (2019) Effects of lanthanum carbonate on bone markers and bone mineral density in incident hemodialysis patients. J Bone Miner Metab 37:1075–1082PubMed
23.
Hain DJ, Marinaro M, Koeper DW, Rosenthal MA, Chillemi S, Huffman JM, Gerbeling T, Pritsiolas JM, Loram LC, Pergola PE (2017) Ferric citrate controls serum phosphorus in dialysis patients: retrospective data. Clin Nephrol 88:12–18PubMedPubMedCentral
24.
Haratake J, Yasunaga C, Ootani A, Shimajiri S, Matsuyama A, Hisaoka M (2015) Peculiar histiocytic lesions with massive lanthanum deposition in dialysis patients treated with lanthanum carbonate. Am J Surg Pathol 39:767–771PubMed
25.
Hattori K, Maeda T, Nishida S, Imanishi M, Sakaguchi M, Amari Y, Moriya T, Hirose Y (2017) Correlation of lanthanum dosage with lanthanum deposition in the gastroduodenal mucosa of dialysis patients. Pathol Int 67:447–452PubMed
26.
Hertel J, Locatelli F, Spasovski G, Dimkovic N, Wanner C (2015) Randomized, double-blind, placebo-controlled, withdrawal study of colestilan after dose titration in chronic kidney disease dialysis patients with hyperphosphatemia. Nephron 130:229–238PubMed
27.
Hjemas BJ, Bovre K, Mathiesen L, Lindstrom JC, Bjerknes K (2019) Interventional study to improve adherence to phosphate binder treatment in dialysis patients. BMC Nephrol 20:178PubMedPubMedCentral
28.
Hoda RS, Sanyal S, Abraham JL, Everett JM, Hundemer GL, Yee E, Lauwers GY, Tolkoff-Rubin N, Misdraji J (2017) Lanthanum deposition from oral lanthanum carbonate in the upper gastrointestinal tract. Histopathology 70:1072–1078PubMedPubMedCentral
29.
Hood CJ, Wolley MJ, Kam AL, Kendrik-Jones JC, Marshall MR (2015) Feasibility study of colestipol as an oral phosphate binder in hemodialysis patients. Nephrology (Carlton) 20:250–256
30.
Hutchison A, Whelton A, Thadhani R, Achenbach H, Vergani A, Wu J, Hall G (2018) Long-term mortality and bone safety in patients with end-stage renal disease receiving lanthanum carbonate. Nephron 140:265–274PubMedPubMedCentral
31.
Hutchison AJ, Wilson RJ, Garafola S, Copley JB (2016) Lanthanum carbonate: safety data after 10 years. Nephrology (Carlton) 21:987–994
32.
Imtiaz R, Atkinson K, Guerinet J, Wilson K, Leidecker J, Zimmerman D (2017) A pilot study of OkKidney, a phosphate counting application in patients on peritoneal dialysis. Perit Dial Int 37:613–618PubMed
33.
Iwamuro M, Urata H, Tanaka T, Kawano S, Kawahara Y, Kimoto K, Okada H (2018) Lanthanum deposition corresponds to white lesions in the stomach. Pathol Res Pract 214:934–939PubMed
34.
Iwamuro M, Urata H, Tanaka T, Kawano S, Kawahara Y, Kimoto K, Okada H (2018) Lanthanum deposition in the stomach in the absence of Helicobacter pylori infection. Intern Med 57:801–806PubMed
35.
36.
Ix JH, Isakova T, Larive B, Raphael KL, Raj DS, Cheung AK, Sprague SM, Fried LF, Gassman JJ, Middleton JP, Flessner MF, Block GA, Wolf M (2019) Effects of nicotinamide and lanthanum carbonate on serum phosphate and fibroblast growth factor-23 in CKD: the COMBINE trial. J Am Soc Nephrol 30:1096–1108PubMed
37.
Jalal D, McFadden M, Dwyer JP, Umanath K, Aguilar E, Yagil Y, Greco B, Sika M, Lewis JB, Greene T, Goral S (2017) Adherence rates to ferric citrate as compared to active control in patients with end stage kidney disease on dialysis. Hemodial Int 21:243–249PubMed
38.
Jansz TT, Neradova A, van Ballegooijen AJ, Verhaar MC, Vervloet MG, Schurgers LJ, van Jaarsveld BC (2018) The role of kidney transplantation and phosphate binder use in vitamin K status. PLoS One 13:e0203157PubMedPubMedCentral
39.
Kalantar-Zadeh K, Parameswaran V, Ficociello LH, Anderson L, Ofsthun NJ, Kwoh C, Mullon C, Kossmann RJ, Coyne DW (2018) Real-world scenario improvements in serum phosphorus levels and pill burden in peritoneal dialysis patients treated with sucroferric oxyhydroxide. Am J Nephrol 47:153–161PubMedPubMedCentral
40.
Keith M, de Sequera P, Clair F, Pedersini R (2016) Lanthanum carbonate oral powder: satisfaction, preference and adherence in French and Spanish patients with end-stage renal disease. Drugs Context 5:212300PubMedPubMedCentral
41.
42.
Ketteler M, Sprague SM, Covic AC, Rastogi A, Spinowitz B, Rakov V, Walpen S, Floege J (2019) Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disease-mineral bone disorder parameters in dialysis patients. Nephrol Dial Transplant 34:1163–1170PubMed
43.
Kim J, Olson K, Butani L (2016) Sevelamer crystals in the mucosa of the gastrointestinal tract in a teenager with end-stage renal disease. Pediatr Nephrol 31:339–341PubMed
44.
Koiwa F, Yokoyama K, Fukagawa M, Akizawa T (2018) Efficacy and safety of sucroferric oxyhydroxide and calcium carbonate in hemodialysis patients. Kidney Int Rep 3:185–192PubMed
45.
Koiwa F, Yokoyama K, Fukagawa M, Akizawa T (2017) Long-term assessment of the safety and efficacy of PA21 (sucroferric oxyhydroxide) in Japanese hemodialysis patients with hyperphosphatemia: an open-label, multicenter, phase III study. J Ren Nutr 27:346–354PubMed
46.
Koiwa F, Yokoyama K, Fukagawa M, Terao A, Akizawa T (2017) Efficacy and safety of sucroferric oxyhydroxide compared with sevelamer hydrochloride in Japanese haemodialysis patients with hyperphosphataemia: a randomized, open-label, multicentre, 12-week phase III study. Nephrology (Carlton) 22:293–300
47.
Komaba H, Kakuta T, Wada T, Hida M, Suga T, Fukagawa M (2019) Nutritional status and survival of maintenance hemodialysis patients receiving lanthanum carbonate. Nephrol Dial Transplant 34:318–325PubMed
48.
Komaba H, Wang M, Taniguchi M, Yamamoto S, Nomura T, Schaubel DE, Smith AR, Zee J, Karaboyas A, Bieber B, Fukagawa M, Tentori F (2017) Initiation of sevelamer and mortality among hemodialysis patients treated with calcium-based phosphate binders. Clin J Am Soc Nephrol 12:1489–1497PubMedPubMedCentral
49.
Kovesdy CP, Lu JL, Wall BM, Gyamlani G, Naseer A, Wallick A, Han Z, Thomas F, Quarles LD, Jarmukli N (2018) Changes with lanthanum carbonate, calcium acetate, and phosphorus restriction in CKD: a randomized controlled trial. Kidney Int Rep 3:897–904PubMedPubMedCentral
50.
Lenglet A, Liabeuf S, El Esper N, Brisset S, Mansour J, Lemaire-Hurtel AS, Mary A, Brazier M, Kamel S, Mentaverri R, Choukroun G, Fournier A, Massy ZA (2017) Efficacy and safety of nicotinamide in haemodialysis patients: the NICOREN study. Nephrol Dial Transplant 32:870–879PubMed
51.
Liabeuf S, Ryckelynck JP, El Esper N, Urena P, Combe C, Dussol B, Fouque D, Vanhille P, Frimat L, Thervet E, Mentaverri R, Prie D, Choukroun G, Collaborators FS (2017) Randomized clinical trial of sevelamer carbonate on serum klotho and fibroblast growth factor 23 in CKD. Clin J Am Soc Nephrol 12:1930–1940PubMedPubMedCentral
52.
Lioufas N, Toussaint ND, Pedagogos E, Elder G, Badve SV, Pascoe E, Valks A, Hawley C, Committee I-CW (2019) Can we IMPROVE cardiovascular outcomes through phosphate lowering in CKD? Rationale and protocol for the IMpact of Phosphate Reduction On Vascular End-points in Chronic Kidney Disease (IMPROVE-CKD) study. BMJ Open 9:e024382PubMedPubMedCentral
53.
Liu Z, Su G, Guo X, Wu Y, Liu X, Zou C, Zhang L, Yang Q, Xu Y, Ma W (2015) Dietary interventions for mineral and bone disorder in people with chronic kidney disease. Cochrane Database Syst Rev 9:CD010350
54.
Locatelli F, Dimkovic N, Spasovski G (2015) Colestilan for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Expert Rev Endocrinol Metab 10:131–142PubMed
55.
Locatelli F, Spasovski G, Dimkovic N, Wanner C (2016) Long-term evaluation of colestilan in chronic kidney disease stage 5 dialysis patients with hyperphosphataemia. Blood Purif 41:247–253PubMed
56.
Lung YF, Sun YS, Lin CK, Uan JY, Huang HH (2016) Synthesis of Mg–Fe–Cl hydrotalcite-like nanoplatelets as an oral phosphate binder: evaluations of phosphorus intercalation activity and cellular cytotoxicity. Sci Rep 6:32458PubMedPubMedCentral
57.
Maruyama N, Otsuki T, Yoshida Y, Nagura C, Kitai M, Shibahara N, Tomita H, Maruyama T, Abe M (2018) Ferric citrate decreases fibroblast growth factor 23 and improves erythropoietin responsiveness in hemodialysis patients. Am J Nephrol 47:406–414PubMed
58.
Matias PJ, Jorge C, Azevedo A, Laranjinha I, Navarro D, Mendes M, Amaral T, Ferreira C, Aires I, Gil C, Stuard S, Ferreira A (2016) Calcium acetate/magnesium carbonate and cardiovascular risk factors in chronic hemodialysis patients. Nephron 132:317–326PubMed
59.
Nagano N, Minegishi A, Ito K, Ando T, Tsutsui T, Ogawa T (2018) Phosphate binders derived from natural ores contain many kinds of metallic elements besides their active ingredient metals. Ther Apher Dial 22:630–634PubMed
60.
Nambiar S, Pillai UK, Devasahayam J, Oliver T, Karippot A (2018) Colonic mucosal ulceration and gastrointestinal bleeding associated with sevelamer crystal deposition in a patient with end stage renal disease. Case Rep Nephrol 2018:4708068PubMedPubMedCentral
61.
Neradova A, Schumacher SP, Hubeek I, Lux P, Schurgers LJ, Vervloet MG (2017) Phosphate binders affect vitamin K concentration by undesired binding, an in vitro study. BMC Nephrol 18:149PubMedPubMedCentral
62.
Nguyen TM, Muller RH, Taupitz M, Schnorr J, Hamm B, Wagner S (2015) Novel oral phosphate binder with nanocrystalline maghemite-phosphate binding capacity and pH effect. Int J Pharm 482:21–26PubMed
63.
Otsuki T, Utsunomiya K, Moriuchi M, Horikoshi S, Okamura M, Suzuki H, Okamura M, Maruyama N, Shibahara N, Abe M (2018) Effect of sucroferric oxyhydroxide on fibroblast growth factor 23 levels in hemodialysis patients. Nephron 140:161–168PubMed
64.
Pai AB, Jang SM, Wegrzyn N (2016) Iron-based phosphate binders—a new element in management of hyperphosphatemia. Expert Opin Drug Metab Toxicol 12:115–127PubMed
65.
Palmer SC, Gardner S, Tonelli M, Mavridis D, Johnson DW, Craig JC, French R, Ruospo M, Strippoli GF (2016) Phosphate-binding agents in adults with CKD: a network meta-analysis of randomized trials. Am J Kidney Dis 68:691–702PubMed
66.
Patel L, Bernard LM, Elder GJ (2016) Sevelamer versus calcium-based binders for treatment of hyperphosphatemia in CKD: a meta-analysis of randomized controlled trials. Clin J Am Soc Nephrol 11:232–244PubMed
67.
Rhee CM, You AS, Koontz Parsons T, Tortorici AR, Bross R, St-Jules DE, Jing J, Lee ML, Benner D, Kovesdy CP, Mehrotra R, Kopple JD, Kalantar-Zadeh K (2017) Effect of high-protein meals during hemodialysis combined with lanthanum carbonate in hypoalbuminemic dialysis patients: findings from the FrEDI randomized controlled trial. Nephrol Dial Transplant 32:1233–1243PubMed
68.
Ruggiero B, Trillini M, Tartaglione L, Rotondi S, Perticucci E, Tripepi R, Aparicio C, Lecchi V, Perna A, Peraro F, Villa D, Ferrari S, Cannata A, Mazzaferro S, Mallamaci F, Zoccali C, Bellasi A, Cozzolino M, Remuzzi G, Ruggenenti P, Kohan DE, ANSWER Study Organization (2019) Effects of sevelamer carbonate in patients with CKD and proteinuria: the ANSWER randomized trial. Am J Kidney Dis 74(3):338–350. https://​doi.​org/​10.​1053/​j.​ajkd.​2019.​01.​029
69.
Ruospo M, Palmer SC, Natale P, Craig JC, Vecchio M, Elder GJ, Strippoli GF (2018) Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD). Cochrane Database Syst Rev 8:CD006023PubMed
70.
Russo D, Bellasi A, Pota A, Russo L, Di Iorio B (2015) Effects of phosphorus-restricted diet and phosphate-binding therapy on outcomes in patients with chronic kidney disease. J Nephrol 28:73–80PubMed
71.
Sherman RA (2016) Hyperphosphatemia in dialysis patients: beyond nonadherence to diet and binders. Am J Kidney Dis 67:182–186PubMed
72.
73.
Sprague SM, Covic AC, Floege J, Ketteler M, Botha J, Chong EM, Rastogi A (2016) Pharmacodynamic effects of sucroferric oxyhydroxide and sevelamer carbonate on vitamin D receptor agonist bioactivity in dialysis patients. Am J Nephrol 44:104–112PubMed
74.
Sprague SM, Floege J (2018) Sucroferric oxyhydroxide for the treatment of hyperphosphatemia. Expert Opin Pharmacother 19:1137–1148PubMed
75.
Sprague SM, Ketteler M, Covic AC, Floege J, Rakov V, Walpen S, Rastogi A (2018) Long-term efficacy and safety of sucroferric oxyhydroxide in African American dialysis patients. Hemodial Int 22:480–491PubMed
76.
St Peter WL, Wazny LD, Weinhandl ED (2018) Phosphate-binder use in US dialysis patients: prevalence, costs, evidence, and policies. Am J Kidney Dis 71:246–253PubMed
77.
Taniguchi K, Kakuta H (2015) Bixalomer, a novel phosphate binder with a small swelling index, improves hyperphosphatemia in chronic kidney disease rat. Eur J Pharmacol 766:129–134PubMed
78.
Tatsuzawa M, Ogawa R, Ohkubo A, Shimojima K, Maeda K, Echizen H, Miyazaki A (2016) Influence of proton pump inhibitors and histamine H2 receptor antagonists on serum phosphorus level control by calcium carbonate in patients undergoing hemodialysis: a retrospective medical chart review. J Pharm Health Care Sci 2:34PubMedPubMedCentral
79.
Thompson S, Manns B, Lloyd A, Hemmelgarn B, MacRae J, Klarenbach S, Unsworth L, Courtney M, Tonelli M (2017) Impact of using two dialyzers in parallel on phosphate clearance in hemodialysis patients: a randomized trial. Nephrol Dial Transplant 32:855–861PubMed
80.
Tieu C, Moreira RK, Song LM, Majumder S, Papadakis KA, Hogan MC (2016) A case report of sevelamer-associated recto-sigmoid ulcers. BMC Gastroenterol 16:20PubMedPubMedCentral
81.
Tsuchida K, Nagai K, Yokota N, Minakuchi J, Kawashima S (2016) Impact of lanthanum carbonate on prognosis of chronic hemodialysis patients: a retrospective cohort study (Kawashima Study). Ther Apher Dial 20:142–148PubMed
82.
Valika AK, Jain D, Jaffe PE, Moeckel G, Brewster UC (2016) A nodular foreign body reaction in a dialysis patient receiving long-term treatment with lanthanum carbonate. Am J Kidney Dis 67:128–132PubMed
83.
Vrdoljak I, Panjkota Krbavcic I, Bituh M, Leko N, Pavlovic D, Vrdoljak Margeta T (2017) The impact of education and cooking methods on serum phosphate levels in patients on hemodialysis: 1-year study. Hemodial Int 21:256–264PubMed
84.
Wald R, Rabbat CG, Girard L, Garg AX, Tennankore K, Tyrwhitt J, Smyth A, Rathe-Skafel A, Gao P, Mazzetti A, Bosch J, Yan AT, Parfrey P, Manns BJ, Walsh M (2017) Two phosphAte taRGets in End-stage renal disease Trial (TARGET): a randomized controlled trial. Clin J Am Soc Nephrol 12:965–973PubMedPubMedCentral
85.
Wang F, Lu X, Zhang J, Xiong R, Li H, Wang S (2018) Effect of lanthanum carbonate on all-cause mortality in patients receiving maintenance hemodialysis: a meta-analysis of randomized controlled trials. Kidney Blood Press Res 43:536–544PubMed
86.
Wu-Wong JR, Chen YW, Wong JT, Wessale JL (2016) Preclinical studies of VS-505: a non-absorbable highly effective phosphate binder. Br J Pharmacol 173:2278–2289PubMedPubMedCentral
87.
Yabuki K, Haratake J, Tsuda Y, Shiba E, Harada H, Yorita K, Uchihashi K, Matsuyama A, Hirata K, Hisaoka M (2018) Lanthanum-induced mucosal alterations in the stomach (lanthanum gastropathy): a comparative study using an animal model. Biol Trace Elem Res 185:36–47PubMed
88.
Yamaguchi T, Ohyama S, Furukawa H, Sato N, Ohnishi I, Kasashima S, Kawashima A, Kayahara M (2016) Sigmoid colon diverticula perforation associated with sevelamer hydrochloride administration: a case report. Ann Med Surg (Lond) 10:57–60
89.
Yokoyama K, Fukagawa M, Akiba T, Nakayama M, Ito K, Hanaki K, Wolf M, Hirakata H (2019) Randomised clinical trial of ferric citrate hydrate on anaemia management in haemodialysis patients with hyperphosphataemia: ASTRIO study. Sci Rep 9:8877PubMedPubMedCentral
90.
Yuste C, Merida E, Hernandez E, Garcia-Santiago A, Rodriguez Y, Munoz T, Gomez GJ, Sevillano A, Praga M (2017) Gastrointestinal complications induced by sevelamer crystals. Clin Kidney J 10:539–544PubMedPubMedCentral
91.
Zhang C, Wang S, Zhao S, Zhang X (2017) Effect of lanthanum carbonate on coronary artery calcification and bone mineral density in maintenance hemodialysis patients with diabetes complicated with adynamic bone disease: a prospective pilot study. Medicine (Baltimore) 96:e8664
Metadaten
Titel
Phosphate binders in chronic kidney disease: an updated narrative review of recent data
verfasst von
Jürgen Floege
Publikationsdatum
01.06.2020
Verlag
Springer International Publishing
Erschienen in
Journal of Nephrology / Ausgabe 3/2020
Print ISSN: 1121-8428
Elektronische ISSN: 1724-6059
DOI
https://doi.org/10.1007/s40620-019-00689-w

Weitere Artikel der Ausgabe 3/2020

Journal of Nephrology 3/2020 Zur Ausgabe

Original Article

Positive association between intra-operative fluid balance and post-operative acute kidney injury in non-cardiac surgery: the NARA-AKI cohort study

Review

Recent insights into sodium and potassium handling by the aldosterone-sensitive distal nephron: implications on pathophysiology and drug discovery

Review

Fibroblast growth factor 23: are we ready to use it in clinical practice?

Editorial

COVID-19 and dialysis: why we should be worried

Original Article

Combination of calcineurin and mTOR inhibitors in kidney transplantation: a propensity score analysis based on current clinical practice

Original Article

Decline in serum uric acid predicts higher risk for mortality in peritoneal dialysis patients—a propensity score analysis

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 | Hypertonie | Nachrichten

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 | Nierenkarzinom | Nachrichten

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 | NSCLC | Nachrichten

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC
weitere anzeigen

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise